WILMINGTON, DE, United States of America

Scott Boiko

This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Astrazeneca Pharmaceuticals LP. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott Boiko. Retrieved from https://idiyas.com/inventor/scott-boiko

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Scott Boiko and His Patent in Oncology Drug Development.

Introduction

Scott Boiko is an inventor associated with Wilmington, Delaware, and AstraZeneca Pharmaceuticals LP. His patent work includes a combination approach involving an antibody-drug conjugate and a CDK9 inhibitor.

Latest Patents

The supplied information identifies 1 patent for Scott Boiko: “Combination of Antibody-Drug Conjugate and CDK9 Inhibitor.” The title describes a therapeutic combination that brings together a targeted drug-delivery approach and inhibition of CDK9, a protein involved in regulating gene expression.

Career Highlights

Boiko is associated with AstraZeneca Pharmaceuticals LP, a pharmaceutical company engaged in drug research and development. The available details connect his inventive work with oncology-related therapeutic strategies.

Collaborations

The supplied information lists Jerome Thomas Mettetal and Justin Robert Cidado as Boiko’s coworkers. Their names are associated with the same professional context, though the information provided does not specify their roles in the patent.

Conclusion

Scott Boiko’s identified patent reflects work on combining an antibody-drug conjugate with a CDK9 inhibitor, and his listed company affiliation is AstraZeneca Pharmaceuticals LP.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…